Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment
- PMID: 21672367
- DOI: 10.1177/147323001103900231
Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment
Abstract
This study investigated household transmission data for influenza (H1N1-2009) in Japan in order to quantify the age-specific risk of infection and estimate the impact of antiviral treatment on the risk of household transmission. Among a total of 1547 households, involving 4609 household contacts, the secondary attack ratio (SAR) was estimated to be 11.4%. School children aged 5 - 18 years dominated the index cases. Age-specific infectiousness and susceptibility were highest among 0 - 4-year olds, with SAR estimated at 19.4% and 29.6%, respectively. Zanamivir treatment within 24 and 24 - 48 h of illness onset in index cases, respectively, reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those not receiving treatment. The preventive performance of antiviral treatment and prophylaxis should be further examined in randomized controlled trials.
Similar articles
-
Secondary attack rate of pandemic influenza A(H1N1) 2009 in Western Australian households, 29 May-7 August 2009.Euro Surveill. 2011 Jan 20;16(3):19765. Euro Surveill. 2011. PMID: 21262182
-
The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.Influenza Other Respir Viruses. 2019 Mar;13(2):123-132. doi: 10.1111/irv.12590. Epub 2018 Dec 28. Influenza Other Respir Viruses. 2019. PMID: 29989680 Free PMC article.
-
Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009.J Infect. 2010 Oct;61(4):284-8. doi: 10.1016/j.jinf.2010.06.019. Epub 2010 Jul 27. J Infect. 2010. PMID: 20670650
-
Antiviral drugs for influenza 2013-2014.Med Lett Drugs Ther. 2014 Jan 20;56(1434):6-8. Med Lett Drugs Ther. 2014. PMID: 24457560 Review. No abstract available.
-
Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb 10. Antivir Ther. 2015. PMID: 25667992 Review.
Cited by 23 articles
-
Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.BMC Infect Dis. 2021 Aug 9;21(1):777. doi: 10.1186/s12879-021-06494-w. BMC Infect Dis. 2021. PMID: 34372769 Free PMC article.
-
Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment.Clin Infect Dis. 2022 Feb 11;74(3):532-540. doi: 10.1093/cid/ciab625. Clin Infect Dis. 2022. PMID: 34245250 Free PMC article.
-
Reconstructing the household transmission of influenza in the suburbs of Tokyo based on clinical cases.Theor Biol Med Model. 2021 Feb 10;18(1):7. doi: 10.1186/s12976-021-00138-x. Theor Biol Med Model. 2021. PMID: 33568160 Free PMC article.
-
Efficacy of baloxavir marboxil on household transmission of influenza infection.J Pharm Health Care Sci. 2020 Oct 1;6:21. doi: 10.1186/s40780-020-00178-4. eCollection 2020. J Pharm Health Care Sci. 2020. PMID: 33014405 Free PMC article.
-
Virulence-mediated infectiousness and activity trade-offs and their impact on transmission potential of influenza patients.Proc Biol Sci. 2020 May 27;287(1927):20200496. doi: 10.1098/rspb.2020.0496. Epub 2020 May 13. Proc Biol Sci. 2020. PMID: 32396798 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
